Sign inJoin waitlistJoin the waitlist

Ankur Varma

Associate Program Director · University of Arkansas for Medical Sciences (UAMS) College of Medicine

Credentials: · · · · · · · ·

History

University of Texas M D Anderson Cancer Center
2018–2020
Hematology and Medical Oncology
Baylor College of Medicine
2015–2018
Internal Medicine
University of Texas Health Science Center
2012–2015
University of Texas School Public Health, Houston
West Bengal University of Health Sciences in Kolkata, India
2005–2009

Research

Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma
Haematologica · 2021 · 127 citations
Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases
Journal of Clinical Oncology · 2015 · 102 citations
Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?
Blood · 2020 · 55 citations

Qaiser Bashir
13 papers
Richard Champlin
13 papers
Uday Popat
13 papers
Chitra Hosing
11 papers
Muzaffar Qazilbash
11 papers
Partow Kebriaei
9 papers
Amin Alousi
8 papers
Samer Srour
8 papers
Sunita Nathan
8 papers
Celalettin Ustun
7 papers
Robert Orlowski
7 papers
Stefan Ciurea
7 papers

Clinical trials

JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation
Principal investigator · Unknown · Phase 1
Jasper Therapeutics, Inc.
2020–2023
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027